Is JAZZ Still the Best Cannabis Stock After Federal Rescheduling?
Jazz Pharmaceuticals pairs its FDA-approved CBD blockbuster with a diversified drug portfolio, offering medical cannabis exposure despite ongoing pipeline risks.
Zacks
More News
GTBIF Stock Climbs 17.5% in Three Months: Time to Invest or Cash Out?
Green Thumb has surged 17.5% in three months as regulatory progress, Q1 growth and buybacks lift sentiment, but competition and pricing pressure persist.
Zacks
Cannabis Operator Cresco Down 28.5% YTD: How to Play the Stock?
CRLBF is down 28.5% YTD as revenue pressure and competition persist, but retail expansion and improving estimates could shape its next move.
Zacks
MSOS Hits 2026 High: Which Cannabis Stock Could Light Up Portfolios Ahead Of DEA Hearing?
The cannabis ETF has surged 104% over the past year, outperforming both the North American Marijuana Index and the S&P 500.
Stocktwits
Verano Advances U.S. Exchange Uplisting Plans: Time to Invest?
VRNO's reverse split and prior U.S. redomestication support potential exchange uplisting plans as the company expands stores and product offerings.
Zacks
Curaleaf Prepares for US Exchange Uplisting: Time to Invest?
CURLF's reverse stock split and Delaware domestication plan signal preparation for a potential U.S. uplisting as revenue and international growth improve.
Zacks
Schedule III for Some, Not All: Understanding the DOJ's Cannabis Shift
DOJ narrows cannabis reform, shifting select marijuana products to Schedule III while leaving broader federal restrictions intact.
Zacks
Green Thumb Industries Inc. (GTBIF) Moves 10.0% Higher: Will This Strength Last?
Green Thumb Industries Inc. (GTBIF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks
Weedcoin Jumps In Minutes After Trump’s Marijuana Shake-Up Speculation Sparks Sector Frenzy
Cannabis stocks and ETFs rallied sharply, with names like TLRY, GTBIF, TCNNF, and IIPR jumping 6% to over 20% in midday trade.
Stocktwits
Curaleaf Launches Buyback Program: Time to Get Bullish on the Stock?
CURLF's $83M buyback lifts shares, but U.S. pricing pressure and rising losses cloud the outlook despite strong international growth momentum.